Literature DB >> 19808246

Can we personalize treatment for kidney diseases?

Brad H Rovin1, Alison M McKinley, Daniel J Birmingham.   

Abstract

The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to kidney diseases. Nonetheless, kidney disorders present a variety of opportunities to personalize medicine. Here, the heterogeneity of kidney disorders is reviewed to provide a rationale for pursuing personalized medicine. Data on adjusting therapy on the basis of pharmacogenetics/genomics and pharmacodynamics are summarized to demonstrate where the field is, and biomarker studies that reflect the future of personalized medicine are discussed. The goal of this review is to demonstrate that we can personalize therapy for kidney diseases but that considerable investment in new research will be required for personalized medicine to be routinely used in nephrology clinics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808246     DOI: 10.2215/CJN.04140609

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  9 in total

Review 1.  Genetic testing in renal disease.

Authors:  Detlef Bockenhauer; Alan J Medlar; Emma Ashton; Robert Kleta; Nick Lench
Journal:  Pediatr Nephrol       Date:  2011-05-27       Impact factor: 3.714

2.  Training the next generation's nephrology workforce.

Authors:  Jeffrey S Berns; David H Ellison; Stuart L Linas; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 8.237

Review 3.  Treatment of proliferative lupus nephritis: a slowly changing landscape.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Nat Rev Nephrol       Date:  2010-12-21       Impact factor: 28.314

Review 4.  Genetics of Lupus Nephritis: Clinical Implications.

Authors:  Melissa E Munroe; Judith A James
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

5.  Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli.

Authors:  Anjali A Satoskar; John P Shapiro; Cherri N Bott; Huijuan Song; Gyongyi M Nadasdy; Sergey V Brodsky; Lee A Hebert; Daniel J Birmingham; Tibor Nadasdy; Michael A Freitas; Brad H Rovin
Journal:  Mod Pathol       Date:  2012-01-27       Impact factor: 7.842

6.  Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis.

Authors:  Gema Fernandez-Juarez; Javier Villacorta; Gloria Ruiz-Roso; Nayara Panizo; Isabel Martinez-Marín; Helena Marco; Pilar Arrizabalaga; Montserrat Díaz; Vanessa Perez-Gómez; Marco Vaca; Eva Rodríguez; Carmen Cobelo; Loreto Fernandez; Ana Avila; Manuel Praga; Carlos Quereda; Alberto Ortiz
Journal:  Clin Kidney J       Date:  2016-05-24

7.  Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine.

Authors:  Hans-Joachim Anders; Marc Weidenbusch; Brad Rovin
Journal:  Clin Kidney J       Date:  2015-08-27

8.  Chapter 2: General principles in the management of glomerular disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06

9.  Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant.

Authors:  H S Ciftci; E Demir; M S Karadeniz; T Tefik; I Nane; F S Oguz; F Aydin; A Turkmen
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.